Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 89-94

  Barrail, Aurélie ^a   Tiec, Clotilde Le ^a   Paci Bonaventure, Sabine ^a   Furlan, Valérie ^a   Vincent, Isabelle ^a   Taburet, Anne Marie ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Amprenavir; HPLC assay; Protein binding; Therapeutic drug monitoring; Ultrafiltration

Indexed keywords

AMPRENAVIR; LOPINAVIR; NELFINAVIR; RITONAVIR; CARBAMIC ACID DERIVATIVE; PROTEINASE INHIBITOR; SULFONAMIDE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RETENTION; EQUILIBRIUM DIALYSIS; FRACTIONATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; ULTRAFILTRATION; BLOOD; DRUG INTERACTION; DRUG MONITORING; METABOLISM; METHODOLOGY; PROTEIN BINDING;

AREA UNDER CURVE; CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; DRUG MONITORING; HIV PROTEASE INHIBITORS; HUMANS; PROTEIN BINDING; SULFONAMIDES; ULTRAFILTRATION;

EID: 33745504726     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000188018.26680.98     Document Type: Article

References (23)

1. Eron JJ, Vernazza P. Alternative strategies for anti-HIV treatment. AIDS. 2001;15:S161-S169.
2. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999;36:289-304.
3. Sadler BM, Gillotin C, Lou Y, et al. In vivo effect of α1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 2001;45:852-856.
4. Sadler BM, Stein DS. Clinical pharmacology and pharmacokinetics of amprenavir. Ann Pharmacother. 2002;36:102-118.
5. Goujard C, Vincent I, Meynard JL, et al. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2003;47:118-123.
6. Peytavin G, Lamotte C, Duval X, et al. Amprenavir (APV) plasma concentrations are dramatically decreased by association with ABT378/r in HIV-infected patients. 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk; 2001.
7. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother. 2002;46:746-754.
8. Piliero PJ. The utility of inhibitory quotients in determining the relative potency of protease inhibitors. AIDS. 2002;16:799-800.
9. Aarnoutse RE, Schapiro JM, Boucher CAB, et al. Therapeutic drug monitoring: an aid to optimizing response to antiretroviral drugs? Drugs. 2003;63:741-753.
10. Raguin G, Chêne G, Morand-Joubert L, et al. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther. 2004;9:615-625.
11. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir/ritonavir combination in heavily pretreated HIV-infected patients. Clin Pharmacol Ther. 2004;75:310-323.
12. Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs. Clin Pharmacokinet. 1992;23:449-468.
13. Jayewardene AL, Zhu F, Aweeka FT, et al. Simple high performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J Chromatogr. 1998;707:203-211.
14. Guidance for Industry. Bioanalytical Method Validation, U.S. Department of Health and Human Services Food and Drug Evaluation and Research Center for Veterinary Medicine, May 2001. Available at: http://www.fda.gov/cder/guidance/ 4252fnl.pdf. Accessed September 2005.
15. Keil K, Frerichs VA, DiFrancesco R, et al. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir and saquinavir in heparinized human plasma. Ther Drug Monit. 2003;25:340-346.
16. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit. 2003;25:393-399.
17. Tribut O, Arvieux C, Michelet C, et al. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit. 2002;24:554-562.
18. Titier K, Lagrange F, Pehourcq F, et al. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. Ther Drug Monit. 2002;24:417-424.
19. Poirier JM, Robidou P, Jaillon P. Simple and simultaneous determination of the HIV-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. Ther Drug Monit. 2005;27:186-192.
20. Leibenguth P, Le Guellec C, Besnier JM, et al. Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection. Ther Drug Monit. 2001;23:679-688.
21. Livingston DJ, Pazhanisamy S, Porter DJT, et al. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis. 1995;172:1238-1245.
22. Zhang XQ, Schooley RT, Gerber JG. The effect of increasing α1-acid glycoprotein concentration on the antiretroviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis. 1999;80:1833-1837.
23. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-121.